Cargando…
Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
MS patients were one of the first populations vaccinated in Iran. To date, the most used vaccine brand on Iranian MS patients is Sinopharm COVID-19 vaccine. Here is the first study on the adverse events after the first dose of Sinopharm vaccine on 583 Iranian MS patients. A Google form link was sent...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458008/ https://www.ncbi.nlm.nih.gov/pubmed/34579974 http://dx.doi.org/10.1016/j.vaccine.2021.09.030 |